Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
AYTU | US
0.09
3.57%
Healthcare
Biotechnology
30/06/2024
09/03/2026
2.61
2.52
2.68
2.37
Aytu Biopharma Inc. a commercial-stage pharmaceutical company focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates into two segments Rx segment and Consumer Health segment. The Rx segment consisting of prescription pharmaceutical products sold through third party wholesalers. The Consumer Health segment which consists of various consumer health products sell directly to consumers. It also offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from six years and older; and Cotempla XR-ODT for the treatment of ADHD in patients from six to seventeen years old. In addition the company provides Karbinal ER for the treatment of seasonal and perennial allergies; and Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency. The company was formerly known as Aytu BioScience Inc. and changed its name to Aytu Biopharma Inc. in March 2021. Aytu Biopharma Inc. was incorporated in 2015 and is headquartered in Englewood Colorado.
View LessStrength based on increasing price with high volume
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
45.4%1 month
48.9%3 months
54.5%6 months
63.9%-
9.96
0.51
0.55
0.13
1.14
0.11
-
6.11M
16.05M
16.05M
-
-4.45
-
-41.50
-47.24
10.14
5.33
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.53
Range1M
0.56
Range3M
0.94
Rel. volume
1.34
Price X volume
161.41K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Evaxion Biotech A/S | EVAX | Biotechnology | 3.08 | 17.18M | -4.35% | n/a | 837.11% |
| NeuroSense Therapeutics Ltd. Ordinary Shares | NRSN | Biotechnology | 0.8404 | 16.65M | -2.96% | n/a | -2.11% |
| VistaGen Therapeutics Inc | VTGN | Biotechnology | 0.615 | 16.64M | 1.20% | n/a | 1.90% |
| GeoVax Labs Inc | GOVX | Biotechnology | 1.92 | 16.37M | 7.26% | n/a | -6.03% |
| Genenta Science S.p.A | GNTA | Biotechnology | 0.8574 | 15.62M | -0.31% | n/a | 0.00% |
| ImmunoCellular Therapeutics Ltd | IMUC | Biotechnology | 0.133 | 14.85M | 0.02 | -82.78% | |
| ADTX | ADTX | Biotechnology | 3.47 | 14.65M | 645.27% | n/a | 122.46% |
| Marker Therapeutics Inc | MRKR | Biotechnology | 1.47 | 13.12M | 6.52% | n/a | 0.00% |
| DarT Bioscience Inc | DARE | Biotechnology | 1.53 | 13.08M | 0.00% | 0.12 | 218.34% |
| CytoMed Therapeutics Limited Ordinary Shares | GDTC | Biotechnology | 1.06 | 12.23M | 0.95% | n/a | 3.98% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.6001 | 11.60M | -5.42% | n/a | 58.43% |
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 3.98 | 6.06M | -4.33% | n/a | 204.46% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.47 | 3.75M | -0.67% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.39 | 3.71M | -1.76% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.46 | 1.36M | 2.93% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.008 | 737.72K | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 1.14 | 0.53 | Expensive |
| Ent. to Revenue | 0.11 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.51 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 54.53 | 72.80 | Lower Risk |
| Debt to Equity | 0.55 | -1.23 | Expensive |
| Debt to Assets | 0.13 | 0.25 | Cheaper |
| Market Cap | 16.05M | 3.66B | Emerging |